Mogo Moringa LLC Announces Voluntary Recall of Select Lots of Moringa Capsules Due to Possible Salmonella Contamination
Mogo Moringa LLC has initiated a voluntary recall of specific lots of Moringa Capsules due to potential contamination with Salmonella. The recall was announced following the identification of the pathogen risk in select batches produced in Saint Louis, Missouri.
This recall affects Mogo Moringa LLC, distributors of the specific Moringa Capsule lots, and consumers who have purchased these dietary supplements. It also affects retail-level compliance and quality teams responsible for product removal.
The presence of Salmonella in a dietary supplement represents a significant microbiological hazard that can lead to serious infection. From a regulatory perspective, this suggests a potential breakdown in Current Good Manufacturing Practices (cGMP) or raw material testing protocols. Quality teams may need to investigate whether this is an isolated incident or indicative of broader environmental contamination within the production facility.
QA teams should immediately verify if affected lot numbers are in inventory, secure suspected product to prevent distribution, and initiate consumer notification protocols as per the company's recall plan. Review supplier qualification records for the raw Moringa source to identify the origin of the potential contamination.
FOR IMMEDIATE RELEASE Mogo Moringa LLC Announces Voluntary Recall of Select Lots of Moringa Capsules Due to Possible Salmonella Contamination Saint Louis, MO — May 25, 2026 — Mogo Moringa LLC, based in Saint Louis, Missouri, is voluntarily recalling specific lots of its Mogo Moringa Capsules after d
Open in openFDA / FDA.gov